

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)



(10) International Publication Number
WO 2022/178428 A1

(51) International Patent Classification:

A61K 31/428 (2006.01) C07D 417/12 (2006.01)
C07D 277/82 (2006.01)

(21) International Application Number:

PCT/US2022/017334

(22) International Filing Date:

22 February 2022 (22.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/152,110 22 February 2021 (22.02.2021) US

(71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney Avenue, New Haven, Connecticut 06510 (US).

(72) Inventors: SPIEGEL, David; 94 Morris Cove Road, New Haven, Connecticut 06512 (US). HOWELL, Rebecca; 44 Park Avenue, Hamden, Connecticut 06517 (US). MCDON-


ALD, David; 814 Orange Street, New Haven, Connecticut 06511 (US).

(74) Agent: SILVA, Domingos J. et al.; SAUL EWING ARNSTEIN & LEHR LLP, Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, Pennsylvania 19102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: TARGETED BIFUNCTIONAL DEGRADERS AND METHODS USING SAME

FIG. 1



Bifunctional molecule

1. Cross blood brain barrier
2. Bind target protein
3. Remove target protein
peripheral sink
lysosomal degradation

Modular system to develop
platform for degradation of
neurological proteins

Low density lipoprotein receptor
related protein 1 (LRP1)

LRP1 mediated transcytosis and
degradation

(57) Abstract: The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of an extracellular or cell surface protein. In certain embodiments, the extracellular protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, and/or reduction in concentration of the protein in the subject. In some embodiments, the disease and/or disorder is a neurological disease and/or disorder. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the amount of the extracellular or cell surface protein in the brain, thus treating, ameliorating, or preventing the disease and/or disorder.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*